Does Blue Cross Blue Shield of Massachusetts Cover Jardiance?

What Is Jardiance and Why Does Coverage Matter?

Jardiance (empagliflozin) is an SGLT2 inhibitor approved by the FDA for glycemic control in type 2 diabetes, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, treatment of heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and slowing progression of chronic kidney disease (CKD). [1] Because it carries multiple FDA-approved indications, the indication listed on a prior authorization request can directly affect approval odds.

Clinical Evidence Behind Jardiance

The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced the rate of 3-point major adverse cardiovascular events (MACE) by 14% relative to placebo (10.5% vs. 12.1%, hazard ratio 0.86, 95% CI 0.74 to 0.99, P<0.001 for non-inferiority). [2] Cardiovascular death was cut by 38% (3.7% vs. 5.9%). [2]

The EMPEROR-Reduced trial (N=3,730) found empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001). [3] EMPEROR-Preserved (N=5,988) extended that benefit to HFpEF populations. [4]

For CKD, the EMPA-KIDNEY trial (N=6,609) showed empagliflozin cut the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001). [5]

This evidence base is why the 2024 American Diabetes Association Standards of Care recommend SGLT2 inhibitors for patients with type 2 diabetes who also have atherosclerotic cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c. [6]

Why Tier Placement Drives Your Actual Cost

Brand-name drugs placed on Tier 3 carry typical commercial copays of $45 to $100 per 30-day supply on many BCBS MA plans. Tier 4 placement can push that figure above $150 before any savings programs apply. Knowing the tier before filling the prescription lets patients prepare financially and decide whether to pursue a formulary exception.

How BCBS MA Formularies Work

Blue Cross Blue Shield of Massachusetts operates several distinct formulary structures depending on whether coverage comes through an employer-sponsored plan, an individual/family plan purchased through the Massachusetts Health Connector, or a Medicare Advantage or Part D plan. Each formulary is published annually and can change on January 1 of each plan year.

Commercial and Employer Plan Formularies

Most BCBS MA commercial plans use a five-tier formulary:

• Tier 1: Low-cost generics
• Tier 2: Preferred generics and some low-cost brands
• Tier 3: Preferred brand-name drugs
• Tier 4: Non-preferred brand-name drugs
• Tier 5: Specialty drugs

Jardiance most commonly appears at Tier 3 or Tier 4 on BCBS MA commercial formularies. Its placement can differ between the Blue Choice PPO, HMO Blue, and Blue Cross TM HMO product lines. Checking your specific plan's Summary of Benefits and Coverage (SBC) or the live drug lookup tool at bcbsma.com gives the most accurate tier assignment for your current plan year.

Step Therapy Requirements

BCBS MA, in line with standard managed-care practice, often requires step therapy before approving a brand-name SGLT2 inhibitor. Step therapy means a patient must first try and either fail or have a documented contraindication to a lower-cost alternative. [7] For Jardiance, the typical first-step requirement is metformin, which carries an A-level recommendation in the ADA Standards of Care as initial pharmacotherapy for most patients with type 2 diabetes who tolerate it. [6]

If metformin is contraindicated (eGFR <30 mL/min/1.73m² or intolerance), or if the prescribing clinician documents a specific indication that makes SGLT2 therapy the appropriate first choice (such as established heart failure or CKD stage 3 to 4), that documentation supports bypassing the step-therapy requirement.

Medicare Part D and Medicare Advantage

Medicare formularies are governed by CMS rules and differ substantially from commercial plan formularies. [8] The Jardiance manufacturer savings card (Boehringer Ingelheim/Eli Lilly) is explicitly not valid for patients enrolled in Medicare, Medicaid, or any other federal or state government-funded program. [9] Medicare Part D enrollees should ask their pharmacist about the Low Income Subsidy (LIS) or Extra Help program if cost is a barrier. [8]

Prior Authorization for Jardiance Under BCBS MA

Prior authorization (PA) is a formal review process in which the insurer evaluates whether a drug is medically necessary before agreeing to cover it at the formulary benefit level. Most BCBS MA commercial plans require PA for Jardiance. [7]

What the PA Request Must Include

A well-constructed PA submission typically includes:

1. The specific FDA-approved indication being treated (type 2 diabetes, heart failure, or CKD)
2. Documented HbA1c level and date of measurement for diabetes indications
3. Evidence of step-therapy completion (metformin trial, dose, duration, and reason for discontinuation if applicable)
4. Relevant comorbidities: ASCVD diagnosis, eGFR value, echocardiographic data for heart failure, or UACR for CKD
5. Prescriber NPI and DEA number
6. Current medication list

The 2024 ADA Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with proven cardiovascular benefit should be considered independent of baseline HbA1c." [6] Quoting this guideline language directly in the PA narrative strengthens the clinical justification.

Typical PA Decision Timeline

Massachusetts law requires health insurers to respond to standard PA requests within 3 business days and urgent requests within 24 hours. [10] If the PA is denied, a written denial notice with the specific clinical criteria not met must be provided. [10]

Step Therapy Exception Requests

Massachusetts enacted step-therapy reform legislation that allows patients to request a step-therapy exception when: the required alternative drug is contraindicated, has previously been tried and failed, or would cause harm based on the patient's clinical history. [10] Physicians should document these criteria explicitly in the exception request letter rather than relying on verbal communication with the plan.

What to Do if BCBS MA Denies Jardiance Coverage

A denial is not a final answer. The appeals process is structured, and understanding each level improves the odds of reversal.

Level 1: Internal Appeal

File a written internal appeal within 180 days of receiving the denial notice (check your plan's specific deadline in the denial letter). Submit all supporting clinical documentation: the relevant trial data (EMPA-REG OUTCOME, EMPEROR-Reduced, EMPA-KIDNEY), applicable guideline excerpts from the ADA [6] and the American Heart Association/American College of Cardiology heart failure guidelines, [11] and a letter from the prescribing physician explaining medical necessity.

Level 2: External Independent Review

If the internal appeal is denied, Massachusetts law grants patients the right to an external independent review by a state-certified Independent Review Organization (IRO). [10] The IRO decision is binding on the insurer for coverage determinations. External review requests must generally be filed within 4 months of the internal appeal denial.

Level 3: Massachusetts Insurance Commissioner Complaint

Patients who believe their insurer violated state law during the appeals process may file a complaint with the Massachusetts Division of Insurance. [12] This step is rarely necessary if the external IRO review is pursued, but it is available.

Cost Without Insurance or After Denial

The list price for a 30-day supply of Jardiance 10 mg is approximately $620 to $680 at major U.S. Pharmacies as of early 2025. For patients without coverage or after a denial:

Manufacturer Savings Card

The Jardiance Savings Card, offered by Boehringer Ingelheim and Eli Lilly, reduces the monthly copay to as low as $10 for eligible commercially insured patients and caps out-of-pocket costs at $150 per month for uninsured patients who qualify. [9] Eligibility requires that the patient is not enrolled in any federal or state government health care program.

GoodRx and Pharmacy Discount Programs

GoodRx and similar pharmacy discount services can reduce the cash price of Jardiance to roughly $480 to $540 per month at certain pharmacies. These prices fluctuate and should be verified at the point of purchase.

Therapeutic Alternatives That May Have Lower Tier Placement

If Jardiance coverage is definitively unavailable, clinicians may consider:

• Farxiga (dapagliflozin): Also an SGLT2 inhibitor with FDA approval for type 2 diabetes, HFrEF, HFpEF, and CKD. The DAPA-HF trial (N=4,744) showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65 to 0.85, P<0.001). [13] BCBS MA may place dapagliflozin on a different tier.
• Invokana (canagliflozin): FDA-approved for type 2 diabetes and CKD. CREDENCE (N=4,401) showed canagliflozin reduced the primary composite kidney outcome by 30% (HR 0.70, 95% CI 0.59 to 0.82, P<0.001). [14]
• GLP-1 receptor agonists: Ozempic (semaglutide) or Trulicity (dulaglutide) may be covered at a lower tier depending on the plan formulary and may serve as appropriate alternatives for cardiovascular risk reduction when SGLT2 inhibitors are not accessible.

Switching drug classes should always involve a shared clinical decision between patient and provider, weighing the specific indications, renal function (eGFR affects SGLT2 dosing thresholds), and individual cardiovascular risk profile.

How to Verify Your Specific BCBS MA Plan Coverage

Coverage details vary significantly between individual BCBS MA plan products. The most reliable verification steps are:

Step 1: Use the BCBS MA Drug Lookup Tool

Log in to your member portal at bcbsma.com and use the prescription drug lookup (formulary search) function. Enter "empagliflozin" or "Jardiance" and your specific plan name to see the exact tier, PA requirements, and quantity limits.

Step 2: Call Member Services

The member services number appears on the back of your BCBS MA insurance card. Ask specifically: (a) what tier Jardiance is on your plan, (b) whether PA is required, (c) what the step-therapy criteria are, and (d) what your copay or coinsurance will be after deductible.

Step 3: Ask Your Pharmacist to Run a Test Claim

Before prescribing, a pharmacist can run a test claim (also called a benefit check or adjudication test) to see exactly what your plan will pay and what your estimated out-of-pocket cost will be for that specific fill.

Step 4: Confirm the Plan Year Formulary

BCBS MA formularies update on January 1 each year. A drug covered at Tier 3 in 2024 may move to Tier 4 (or be removed) in 2025. Confirm coverage at the start of each plan year and whenever your employer changes benefit carriers.

SGLT2 Inhibitors and Massachusetts Prescribing Context

Massachusetts has one of the highest rates of cardiovascular disease management guideline adherence in the country, and BCBS MA has participated in value-based payment arrangements that, in theory, should incentivize appropriate use of evidence-based therapies like SGLT2 inhibitors. [15]

The HealthRX clinical team uses the following decision framework when navigating Jardiance PA requests for BCBS MA patients:

HealthRX BCBS MA Jardiance PA Decision Framework (5 steps):

1. Confirm the primary indication. Type 2 diabetes with CV disease, HF, or CKD carries the strongest guideline support and the most compelling PA narrative.
2. Document step-therapy completion or exemption. Metformin trial details (dose, duration, reason for stopping) or a clear contraindication note (eGFR <30, lactic acidosis history).
3. Attach trial data. Print the EMPA-REG OUTCOME abstract [2] and the relevant ADA guideline page [6] as supporting documents.
4. Use the ADA language verbatim. Quoting guideline text in the PA letter reduces reviewer discretion.
5. Pre-schedule the appeal. If PA takes longer than 3 business days or is denied, begin the Level 1 internal appeal within 24 hours of denial to preserve the 180-day window.

This framework is not a guarantee of approval, but it addresses the most common reasons BCBS MA denies SGLT2 inhibitor PA requests.

Special Populations: Pregnancy, Pediatrics, and Renal Impairment

Pregnancy

Jardiance is FDA Pregnancy Category not assigned (post-2015 labeling), but the prescribing information warns against use during the second and third trimesters due to potential fetal renal effects. [1] BCBS MA will generally not approve Jardiance for pregnant patients, and clinical guidelines do not support its use in pregnancy. The ADA recommends insulin as the preferred pharmacologic agent for managing diabetes in pregnancy. [6]

Pediatric Patients

The FDA approved empagliflozin for children aged 10 and older with type 2 diabetes in December 2023. [1] Coverage for pediatric patients under BCBS MA may require additional documentation of failed lifestyle intervention and metformin therapy, consistent with standard step-therapy protocols.

Renal Impairment

The FDA-approved labeling for Jardiance specifies that empagliflozin's glycemic efficacy diminishes significantly when eGFR falls below 45 mL/min/1.73m², but the cardiorenal protective effects persist at lower eGFR values. [1] The EMPA-KIDNEY trial enrolled patients with eGFR as low as 20 mL/min/1.73m². [5] When prescribing for CKD at reduced eGFR, explicitly noting the cardiorenal (not glycemic) indication in the PA request aligns the submission with FDA-approved labeling and guideline support. [6]